Taiho Ventures
01 — Mandate

Capital, witha sixty-yearresearch lineage.

Taiho Ventures is the corporate venture arm of Taiho Pharmaceutical — a $400M fund investing in early-stage biotech, novel platforms, and the rare modalities that will define the next decade of medicine.

Lab Note · 2026/SP/02
Patient capital,
not patient outcomes.
Fund
$400M AUM
Active
24 companies
02 — Approach

Four wayswe deploy.

We do not run a thematic fund. We invest where Taiho Pharmaceutical's sixty years of operating experience can compound a founder's progress — across four well-defined doors.

A

Discovery

First-in-class molecules and new biology — small molecules, biologics, gene & cell.

B

Platforms

Foundational platforms that compound and shorten the path from target to clinic.

C

Spin-outs

Strategic carve-outs from the Taiho pipeline ready for an independent journey.

D

Adjacent

Opportunistic — diagnostics, devices, and digital health near our therapeutic areas.

Therapeutic
Onc · Imm · Allergy · Bone · Muscle · Rare
Modality
Small Mol · Biologics · Cell & Gene
Stage
Research → Pre-IND · IND→PoC opp.
Geography
Global · ex-Japan focus
03 — Portfolio

Twenty-fourand counting.

AllOncImmPlatCell
Onc
Cullinan
↗ Visit company
RNA
Orna
↗ Visit company
Onc
Halda
↗ Visit company
Plat
Magnet Bio
↗ Visit company
Onc
Werewolf
↗ Visit company
Onc
Harpoon
↗ Visit company
Onc
NextCure
↗ Visit company
Onc
ORIC
↗ Visit company
Imm
Anavo
↗ Visit company
Imm
Dren Bio
↗ Visit company
Onc
Storm Tx
↗ Visit company
AI
Theo
↗ Visit company
Plat
Light Horse
↗ Visit company
Cell
Cellvie
↗ Visit company
Plat
Transition
↗ Visit company
Onc
Vertero
↗ Visit company
04 — Philosophy

We strive to improve human health and contribute to a society enriched by smiles.

The Taiho Pledge · Est. 1963

The pledge is older than most of the molecules we've ever shipped. It is also what governs every term sheet we issue, every board seat we take, and every founder we choose to walk alongside.

05 — Get in touch

Buildingsomething new?

Send us your deck and a hypothesis. We respond to every submission within two weeks — no warm intro required.